Bioarray Genetics is a biotech company located in New Haven, Connecticut. We are committed to transforming cancer treatment decisions and outcomes using gene profiling to provide clinically actionable results to clinicians and patients. Our BA100 Triple Negative Breast Cancer Stratification Test, addresses a significant area of unmet medical need. Until now, no stratification test existed for Triple Negative Breast Cancer (TNBC) Patients like there are for HER2+ and ER+ Breast Cancers. The lack of a stratification test that can identify patients according to their likelihood of treatment response meant that every TNBC Patient would get the same treatment option. It took eight years to understand which TNBC Patients would not achieve a complete response to the standard-of-care chemotherapy. We found part of the answer in what are called Housekeeping Genes – the genes responsible for maintaining the minute-by-minute clockwork in breast tissue cells. Surprisingly, when the Triple Negative Cancer Cells prohibit Housekeeping Genes from doing their jobs, the tumor’s response to the standard-of-care chemotherapy changes. Combining this discovery with others, Bioarray Genetics created the BA100 Triple Negative Breast Cancer Stratification Test. Using the BA100 test, we not only know that approximately 67% of Triple Negative Breast Cancer Patients will not achieve a complete response to the standard-of-care chemotherapy, but we can identify who they are prior to treatment. BA100 is now available to select Oncologists and Patients throughout the United States. For more information, please visit http://bioarray.us/.